Document is current
Any future updates will be listed below
-
Authors
Khouja, Mouhamad https://orcid.org/0000-0002-9892-9461
Jiang, Linmiao https://orcid.org/0000-0002-9009-4236
Pal, Karol https://orcid.org/0000-0002-7726-4691
Stewart, Peter James
Regmi, Binaya https://orcid.org/0009-0003-2663-0983
Schwarz, Martin
Klapper, Wolfram https://orcid.org/0000-0001-7208-4117
Alig, Stefan K. https://orcid.org/0000-0001-6825-702X
Darzentas, Nikos
Kluin-Nelemans, Hanneke C.
Hermine, Olivier
Dreyling, Martin
Gonzalez de Castro, David https://orcid.org/0000-0003-0580-5636
Hoster, Eva https://orcid.org/0000-0002-0749-1389
Pott, Christiane https://orcid.org/0009-0005-9260-8340
,
- License Information
-
More Information
Article History
Received: 26 April 2024
Revised: 29 July 2024
Accepted: 6 August 2024
First Online: 16 September 2024
Competing interests
: MK, LJ, KP, PJS, BR, MS, WK, SKCA, HCKN, OH, ND, EH, CP: No COI., MD Research Support: Abbvie, Bayer, BMS/Celgene, Gilead/Kite, Janssen, Lilly, Roche, Speaker Honoraria: AstraZeneca, Beigene, Gilead/Kite, Janssen, Lilly, Novartis, Roche, Advisory Board: Abbvie, AstraZeneca, Beigene, BMS/Celgene, Gilead/Kite, Janssen, Lilly/loxo, Novartis, Roche, D.G: founder and holds stock on Univ8. Genomics Ltd.
: Both clinical trials were led according to the Declaration of Helsinki. All patients gave their written informed consent after have been informed about the purpose and investigational nature of the trial. Prior to initiation, the clinical trial including molecular analysis received approval by the ethics committee of the medical faculty of the Christian-Albrechts-University of Kiel, Germany with the reference number B226/04.
